Inline CCR5-Δ32 Gene Editing During Extracorporeal Blood Circulation

Summary

This note proposes exploring whether an extracorporeal blood-processing device — conceptually similar in form to an ECMO (extracorporeal membrane oxygenation) circuit — could be adapted, or purpose-built, to perform in-line gene editing of blood cells. The specific target is the CCR5-Δ32 mutation, or a functional CRISPR-based knockout of the CCR5 receptor, the primary co-receptor HIV-1 uses to enter CD4+ T-cells.

The goal is to explore whether a dedicated component built into the circuit itself, rather than a separate ex vivo laboratory step, could edit relevant cells during a single extended procedure — rather than requiring the multi-stage collect → culture → edit → reinfuse process used in current CCR5-editing research.

Background and rationale

Individuals carrying two copies of the naturally occurring CCR5-Δ32 mutation are highly resistant to HIV infection. The handful of documented HIV cures to date resulted from bone marrow or stem cell transplants using donors with this mutation — a procedure that works, but is far too risky and resource-intensive for routine use, since it requires ablating the recipient's existing immune system.

Separately, CRISPR-based CCR5 knockout research is already active, generally following an ex vivo model: hematopoietic stem cells are collected, edited outside the body, expanded, and reinfused.

Proposed mechanism

1. Blood is drawn from the patient into an extracorporeal circuit, as in ECMO or apheresis systems.
2. An additional integrated stage exposes relevant cells — particularly hematopoietic stem/progenitor cells mobilized into circulation via existing mobilization agents used in transplant medicine — to a CRISPR-Cas or similar gene-editing payload targeting the CCR5 locus.
3. Edited blood is returned to the patient as part of the same continuous circuit.
4. The procedure would likely run over an extended period, possibly across multiple sessions, to maximize the proportion of edited stem cells reintroduced.

Known technical hurdles

Stem cell targeting

Circulating blood contains relatively few hematopoietic stem cells; most reside in bone marrow. An inline approach would likely need pairing with existing mobilization drugs (e.g., G-CSF, plerixafor) already used in transplant medicine to shift stem cells into peripheral circulation before or during the procedure.

Editing efficiency in continuous flow

Most CRISPR delivery methods are optimized for static, in-lab conditions. Delivering edits efficiently to cells moving through a continuous flow circuit is a nontrivial engineering problem, likely requiring novel delivery chemistry or a semi-continuous, batch-within-circuit design.

Off-target editing and safety monitoring

Any CRISPR approach carries off-target mutation risk. A continuous inline system would need real-time or near-real-time quality control, which does not currently exist for gene editing at this speed.

Immune response to inline reagents

Introducing gene-editing machinery directly into the bloodstream this way differs from current ex vivo methods and would need dedicated safety evaluation.

What would make this worth pursuing

• A feasibility study comparing projected costs and complexity of an inline approach against the current ex vivo pipeline.
• Engineering input from teams working on apheresis/ECMO hardware and on in vivo or inline CRISPR delivery, since this idea sits at the intersection of the two fields.
• Early consultation with labs already active in CCR5-editing HIV cure research to assess whether the inline approach solves a real bottleneck.

Suggested recipients for this concept

Attribution

This concept originated with Jeremy Muchemi. Anyone reviewing or building on this idea is asked to credit the original submission accordingly.